COST REDUCTION IN MEDICINE PURCHASING DIRECTLY WITH INDUSTRY
A study on the direct purchase of medicines with industry
Abstract
In recent years, organizations have found a scenario full of growing challenges in their activities in the face of the current complexity of the so-called Knowledge Society, requiring instruments that enable the improvement of their main resources, relating these activities in order to generate value innovation for the various sectors. . The purpose of this article is to display and evaluate the result of cost reduction in the purchase of Humira and Synagis drugs directly with the pharmaceutical industry. Unimed Cascavel initiated the purchase of Humira in 2017, it is used for the treatment of inflammatory diseases, whereas the purchase of Synagis started in 2018, it is intended for the prevention of severe lower respiratory tract disease caused by the respiratory syncytial virus (RSV). We follow RDC No. 44, of August 17, 2009, which provides for good pharmaceutical practices for sanitary control, product dispensing and service provision, which are related to the way of caring for Unimed, as the center of this activity is the individual (beneficiary and collaborator). The results obtained show that with the introduction of direct purchase, there was a reduction in the average purchase price of Humira of 23.26% and Synagis of 5.34%, in the sum of the results there was a reduction of R $ 48,724.44 in first quarter of 2019. The project standardized the direct purchase model, and can be applied to other co-sisters, reducing financial costs and impacting various audiences in an effective and consistent manner.
Copyright (c) 2020 Renan Willian Back, Fabiano de Lima Tykalowitz, Ricardo Bialeski
This work is licensed under a Creative Commons Attribution 4.0 International License.